Home Healthcare IT Bioanalytical Testing Services Market Size & Share Global Report 2030

Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Type (In-Vitro Virology Testing, In-Vivo Virology Testing, Species-Specific Viral PCR Assays, Method Development, Optimization, Validation, Serology, Immunogenicity, Neutralizing, Antibodies, Biomarker Testing, Pharmacokinetic Testing), By Application (Oncology, Infectious Diseases, Cardiology, Neurology, Gastroenterology), By End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI829DR
Last Updated : Oct 31, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now

Table Of Content

  1. Executive Summary

    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends

    1. Global Bioanalytical Testing Services Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    5. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. In-Vitro Virology Testing
          1. By Value
        3. In-Vivo Virology Testing
          1. By Value
        4. Species-Specific Viral PCR Assays
          1. By Value
        5. Method Development
          1. By Value
        6. Optimization
          1. By Value
        7. Validation
          1. By Value
        8. Serology
          1. By Value
        9. Immunogenicity
          1. By Value
        10. Neutralizing
          1. By Value
        11. Antibodies
          1. By Value
        12. Biomarker Testing
          1. By Value
        13. Pharmacokinetic Testing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Infectious Diseases
          1. By Value
        4. Cardiology
          1. By Value
        5. Neurology
          1. By Value
        6. Gastroenterology
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations
          1. By Value
        4. Contract Research Organizations
          1. By Value
    6. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    5. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. In-Vitro Virology Testing
          1. By Value
        3. In-Vivo Virology Testing
          1. By Value
        4. Species-Specific Viral PCR Assays
          1. By Value
        5. Method Development
          1. By Value
        6. Optimization
          1. By Value
        7. Validation
          1. By Value
        8. Serology
          1. By Value
        9. Immunogenicity
          1. By Value
        10. Neutralizing
          1. By Value
        11. Antibodies
          1. By Value
        12. Biomarker Testing
          1. By Value
        13. Pharmacokinetic Testing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Infectious Diseases
          1. By Value
        4. Cardiology
          1. By Value
        5. Neurology
          1. By Value
        6. Gastroenterology
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations
          1. By Value
        4. Contract Research Organizations
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    5. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. In-Vitro Virology Testing
          1. By Value
        3. In-Vivo Virology Testing
          1. By Value
        4. Species-Specific Viral PCR Assays
          1. By Value
        5. Method Development
          1. By Value
        6. Optimization
          1. By Value
        7. Validation
          1. By Value
        8. Serology
          1. By Value
        9. Immunogenicity
          1. By Value
        10. Neutralizing
          1. By Value
        11. Antibodies
          1. By Value
        12. Biomarker Testing
          1. By Value
        13. Pharmacokinetic Testing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Infectious Diseases
          1. By Value
        4. Cardiology
          1. By Value
        5. Neurology
          1. By Value
        6. Gastroenterology
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations
          1. By Value
        4. Contract Research Organizations
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    5. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. In-Vitro Virology Testing
          1. By Value
        3. In-Vivo Virology Testing
          1. By Value
        4. Species-Specific Viral PCR Assays
          1. By Value
        5. Method Development
          1. By Value
        6. Optimization
          1. By Value
        7. Validation
          1. By Value
        8. Serology
          1. By Value
        9. Immunogenicity
          1. By Value
        10. Neutralizing
          1. By Value
        11. Antibodies
          1. By Value
        12. Biomarker Testing
          1. By Value
        13. Pharmacokinetic Testing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Infectious Diseases
          1. By Value
        4. Cardiology
          1. By Value
        5. Neurology
          1. By Value
        6. Gastroenterology
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations
          1. By Value
        4. Contract Research Organizations
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. In-Vitro Virology Testing
        1. By Value
      3. In-Vivo Virology Testing
        1. By Value
      4. Species-Specific Viral PCR Assays
        1. By Value
      5. Method Development
        1. By Value
      6. Optimization
        1. By Value
      7. Validation
        1. By Value
      8. Serology
        1. By Value
      9. Immunogenicity
        1. By Value
      10. Neutralizing
        1. By Value
      11. Antibodies
        1. By Value
      12. Biomarker Testing
        1. By Value
      13. Pharmacokinetic Testing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Infectious Diseases
        1. By Value
      4. Cardiology
        1. By Value
      5. Neurology
        1. By Value
      6. Gastroenterology
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations
        1. By Value
      4. Contract Research Organizations
        1. By Value
    5. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. In-Vitro Virology Testing
          1. By Value
        3. In-Vivo Virology Testing
          1. By Value
        4. Species-Specific Viral PCR Assays
          1. By Value
        5. Method Development
          1. By Value
        6. Optimization
          1. By Value
        7. Validation
          1. By Value
        8. Serology
          1. By Value
        9. Immunogenicity
          1. By Value
        10. Neutralizing
          1. By Value
        11. Antibodies
          1. By Value
        12. Biomarker Testing
          1. By Value
        13. Pharmacokinetic Testing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Infectious Diseases
          1. By Value
        4. Cardiology
          1. By Value
        5. Neurology
          1. By Value
        6. Gastroenterology
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations
          1. By Value
        4. Contract Research Organizations
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Bioanalytical Testing Services Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Medpace
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Charles River Laboratories
    3. WuXiAppTec
    4. Eurofins Scientific
    5. IQVIA
    6. SGS SA
    7. Covance Inc. (Laboratory Corporation Of America Holdings)
    8. Intertek Group plc
    9. Pra Health Sciences
    10. Syneos Health
    11. LGC Limited
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The cannabis testing services market size was valued at USD 1,120 million in 2019 and is expected to grow with a CAGR of 15.2%. Cannabis testing services involve evaluating the active ingredients and essential chemical compounds in the specified can
Buy Now
Global Report
The global large molecule bioanalytical testing services market size was worth USD 1,5 billion in 2021 and is anticipated to reach ab expected value of USD 3.66 billion by 2030 at a CAGR of 9.7% during the forecast period (2022-2030). Factors such as
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report


We are featured on :